x
Filter:
Filters applied
- Opioids
- CFURemove CFU filter
- IBS-SSSRemove IBS-SSS filter
- 2017 - 2022Remove 2017 - 2022 filter
Keyword
- 5-HT1
- 5-hydroxytryptamine (serotonin)1
- colony-forming units1
- constipation-predominant IBS1
- diarrhea-predominant IBS1
- FDA1
- FODMAPs1
- Food and Drug Administration1
- fructose, oligosaccharides, disaccharides, monosaccharides, and polyols1
- GFD1
- gluten-free diet1
- IBS1
- IBS symptom severity score1
- IBS-C1
- IBS-D1
- irritable bowel syndrome1
- NNT1
- number needed to treat1
- RCT1
- SNRI1
- SSRI1
- TCA1
- TRP1
Opioids
1 Results
- Thematic Review Series on Gastroenterological Diseases
Management Options for Irritable Bowel Syndrome
Mayo Clinic ProceedingsVol. 93Issue 12p1858–1872Published in issue: December, 2018- Michael Camilleri
Cited in Scopus: 51Irritable bowel syndrome (IBS) is associated with diverse pathophysiologic mechanisms. These mechanisms include increased abnormal colonic motility or transit, intestinal or colorectal sensation, increased colonic bile acid concentration, and superficial colonic mucosal inflammation, as well as epithelial barrier dysfunction, neurohormonal up-regulation, and activation of secretory processes in the epithelial layer. Novel approaches to treatment include lifestyle modification, changes in diet, probiotics, and pharmacotherapy directed to the motility, sensation, and intraluminal milieu of patients with IBS.